NCT00206648View on ClinicalTrials.gov

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

PHASE4CompletedINTERVENTIONAL
Enrollment

271

Participants

Timeline

Start Date

March 31, 2003

Study Completion Date

October 31, 2005

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
DRUG

Betaferon/Betaseron

Betaseron 250 µg SC every other day

DRUG

Betaferon/Betaseron

Avonex 30 µg IM once per week

Trial Locations (53)

10003

New York

11501

Mineola

12208

Albany

14215

Buffalo

19104

Philadelphia

19806

Wilmington

21201

Baltimore

22031

Fairfax

24014

Roanoke

27157

Winston-Salem

28801

Asheville

29425

Charleston

30912

Augusta

31405

Savannah

31909

Columbus

32940

Melbourne

33136

Miami

33606

Tampa

33609

Tampa

45409

Dayton

46202

Indianapolis

46805

Fort Wayne

48201

Detroit

50314

Des Moines

55422

Golden Valley

55455

Minneapolis

55905

Rochester

60422

Flossmoor

62703

Springfield

63110

St Louis

64108

Kansas City

66160

Kansas City

71130

Shreveport

73120

Oklahoma City

77030

Houston

85741

Tucson

89509

Reno

92354

Loma Linda

92697

Irvine

94596

Walnut Creek

94598

Walnut Creek

94705

Berkeley

95124

San Jose

95817

Sacramento

97504

Medford

98101

Seattle

98405

Tacoma

90095-1721

Los Angeles

30309-1465

Atlanta

87131-5281

Albuquerque

02905

Providence

K2G 6E2

Nepean

K1H 8L6

Ottawa

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00206648 - An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS | Biotech Hunter | Biotech Hunter